Association Between Non-Nutritive and Nutritive Sweetener Intake and Gastrointestinal Cancer: A Systematic Review and Meta-Analysis
Archives of Endocrinology and Disorders · 04.06.2026 · 2 (2) · 1-38
DOI: 10.46889/aed.2026.2201 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Archives of Endocrinology and Disorders, online erschienen am 04.06.2026. Verfasst von Cecelia Zielke und 25 weiteren Autor:innen. Die Arbeit nennt 103 Literaturangaben.
Abstract (Originalsprache)
Low-calorie sugar alternatives, including Non-Nutritive Sweeteners (NNS) and Nutritive Sweeteners (NS), demonstrate carcinogenic properties in-vivo and in-vitro. Therefore, we systematically reviewed the literature to assess whether intake of the most common NNS and NS; including acesulfame potassium, advantame, aspartame, neotame, saccharin, sucralose, erythritol, isomalt, lactitol, maltitol, sorbitol, xylitol, steviol glycosides and monkfruit; is associated with the five most-common types of gastrointestinal cancer: esophageal, pancreatic, liver, stomach and colorectal. Inclusion criteria were adults between 18 and 65 years and a BMI less than 30 kg/m^2. Exclusion criteria included individuals with metabolic syndrome or H. pylori infection or taking PPIs. Databases searched included PubMed, Embase, Google Scholar, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and WHO Global Index Medicus through March 15th, 2026. Nine studies were included in the meta-analysis. Risk of bias was assessed using RoB 2 and ROBINS-I. Heterogeneity was moderate between studies (Q=16, df=8, I2 ≈ 50%). Stratified by sweetener, no sweetener had a significant association between a reduction or increase in odds of developing gastrointestinal cancer: aspartame (OR ≈ 0.81, 95% CI 0.68-0.97), sucralose (OR = 1.13, 95% CI 1.02-1.25), isomalt (pooled OR ≈ 2.90, 95% CI wide and crossing unity), lactitol (pooled OR ≈ 0.18, 95% CI wide and crossing unity), steviol glycosides (OR = 1.58, 95% CI 1.10-2.26). When pooled across sweetener types and gastrointestinal cancer outcomes, independent exposure to the sweeteners aspartame, sucralose, isomalt, lactitol and steviol glycosides was not significantly associated with GI cancer risk (random-effects OR ≈ 1.07, 95% CI 0.84-1.36). Limitations of evidence included in the review are a relatively small number of independent datasets and reliance on non-independent evidence from meta-analyses and pooled cohort studies.
Zitieren
APA
Zielke, C., Gogna, S., Frozina, L. C., Wu, I., Clark, J. D., Chendra, A. S., Choi, K., Barrett, A. M., Cabebe, M. P., Salapare, C., Mendez, P., Kim, T., Ng, S., Estrella, M. V., Kang, G. P., Kim, M. H., Kim, S. J., Liu, J., Ha, B., …, & Shenoy, A. (2026). Association Between Non-Nutritive and Nutritive Sweetener Intake and Gastrointestinal Cancer: A Systematic Review and Meta-Analysis. Archives of Endocrinology and Disorders, 2(2), 1-38. https://doi.org/10.46889/aed.2026.2201
Vancouver
Zielke C, Gogna S, Frozina LC, Wu I, Clark JD, Chendra AS, et al. Association Between Non-Nutritive and Nutritive Sweetener Intake and Gastrointestinal Cancer: A Systematic Review and Meta-Analysis. Archives of Endocrinology and Disorders. 2026;2(2):1-38. doi:10.46889/aed.2026.2201
BibTeX
@article{Zielke2026,
author = {Zielke, Cecelia and Gogna, Shaan and Frozina, Luke Charles and Wu, Isabel and Clark, Jack David and Chendra, Alicia Sayaka and Choi, Katie and Barrett, Aimee Maureen and Cabebe, Marco Philip and Salapare, Christopher and Mendez, Penelope and Kim, Tiffany and Ng, Sebastian and Estrella, Mylannia Vanessa and Kang, Grayson Pierce and Kim, Morgan Haarim and Kim, Sean J and Liu, Jiayin and Ha, Brandon and Do, Preston Aaron and Chen, Austin and Horng, Samuel and Ganguli, Ritushree and Gogna, Sahil and Tamariz, Tomás Avilés and Shenoy, Ajay},
title = {Association Between Non-Nutritive and Nutritive Sweetener Intake and Gastrointestinal Cancer: A Systematic Review and Meta-Analysis},
journal = {Archives of Endocrinology and Disorders},
year = {2026},
volume = {2},
number = {2},
pages = {1--38},
doi = {10.46889/aed.2026.2201}
}
EUVIMED